PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.235
https://www.valueinhealthjournal.com/article/S1098-3015(18)33535-6/fulltext
Title :
PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33535-6&doi=10.1016/j.jval.2018.09.235
First page :
Section Title :
Open access? :
No
Section Order :
1731